Show simple item record

dc.contributor.authorLewandowski, K
dc.contributor.authorBrabant, G E
dc.date.accessioned2016-05-25T15:28:15Zen
dc.date.available2016-05-25T15:28:15Zen
dc.date.issued2016-03en
dc.identifier.citationPotential clinical utility of copeptin (C-terminal provasopressin) measurements in clinical medicine. 2016, 124 (3):173-7 Exp. Clin. Endocrinol. Diabetesen
dc.identifier.issn1439-3646en
dc.identifier.pmid27008633en
dc.identifier.doi10.1055/s-0035-1569341en
dc.identifier.urihttp://hdl.handle.net/10541/610745en
dc.description.abstractCopeptin is a 39-amino-acids containing glycosylated peptide derived from the C-terminal part of the arginine vasopressin (AVP) precursor. In the process of proteolysis the AVP precursor is processed to AVP, neurophysin II, and copeptin in equimolar amounts. In contrast to AVP, copeptin remains stable for several days at room temperature in serum or plasma. Hence, copeptin serves as a bona fide biomarker of AVP release. We briefly summarise clinical utility of copeptin in the diagnosis of diabetes insipidus. We also discuss potential applications of copeptin measurements in hyponatraemic states, assessment of an anterior pituitary function, as well as a wide range of several acute and chronic medical conditions, such as myocardial infarction, stroke or diabetes mellitus.
dc.language.isoenen
dc.rightsArchived with thanks to Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Associationen
dc.titlePotential clinical utility of copeptin (C-terminal provasopressin) measurements in clinical medicine.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Polanden
dc.identifier.journalExperimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Associationen
html.description.abstractCopeptin is a 39-amino-acids containing glycosylated peptide derived from the C-terminal part of the arginine vasopressin (AVP) precursor. In the process of proteolysis the AVP precursor is processed to AVP, neurophysin II, and copeptin in equimolar amounts. In contrast to AVP, copeptin remains stable for several days at room temperature in serum or plasma. Hence, copeptin serves as a bona fide biomarker of AVP release. We briefly summarise clinical utility of copeptin in the diagnosis of diabetes insipidus. We also discuss potential applications of copeptin measurements in hyponatraemic states, assessment of an anterior pituitary function, as well as a wide range of several acute and chronic medical conditions, such as myocardial infarction, stroke or diabetes mellitus.


This item appears in the following Collection(s)

Show simple item record